Patents by Inventor Mohamad Morsey

Mohamad Morsey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Caninized human antibodies to human IL-4R alpha
    Patent number: 11091556
    Abstract: The present invention provides caninized human anti-human IL-4R? antibodies that have specific sequences and a high binding affinity for canine IL-4R?. The invention also relates to use of these antibodies in the treatment of dogs against atopic dermatitis.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: August 17, 2021
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang
  • Caninized murine antibodies to human PD-1
    Patent number: 10927172
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: February 23, 2021
    Assignee: INTERVET INC.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard Presta
  • Antibodies to Canine Interleukin-4 Receptor Alpha
    Publication number: 20210040223
    Abstract: The present invention discloses antibodies and blocking antibodies to canine IL-4 receptor alpha that have specific sequences and a high binding affinity for canine IL-4 receptor ?. The present invention also discloses the use of the antibodies of the present invention in the treatment of atopic dermatitis in dogs. The present invention further discloses unique epitopes that bind to the antibodies to canine IL-4 receptor alpha.
    Type: Application
    Filed: October 27, 2020
    Publication date: February 11, 2021
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang
  • Antibodies to canine interleukin-4 receptor alpha
    Patent number: 10858437
    Abstract: The present invention discloses antibodies and blocking antibodies to canine IL-4 receptor alpha that have specific sequences and a high binding affinity for canine IL-4 receptor ?. The present invention also discloses the use of the antibodies of the present invention in the treatment of atopic dermatitis in dogs. The present invention further discloses unique epitopes that bind to the antibodies to canine IL-4 receptor alpha.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: December 8, 2020
    Assignee: Intervet, Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang
  • ANTIBODIES AGAINST CANINE PD-1
    Publication number: 20200354450
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: June 5, 2020
    Publication date: November 12, 2020
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • RECOMBINANT NON-PATHOGENIC MAREK'S DISEASE VIRUS CONSTRUCTS ENCODING MULTIPLE HETEROLOGOUS ANTIGENS
    Publication number: 20200323978
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express foreign antigens from three or more avian viruses, along with methods of the use of the multivalent poultry virus vaccines.
    Type: Application
    Filed: October 11, 2018
    Publication date: October 15, 2020
    Applicant: Intervet Inc.
    Inventors: Stephanie M. COOK, Mohamad MORSEY, Ian TARPEY
  • Antibodies against canine PD-1
    Patent number: 10711061
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: July 14, 2020
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • PD-L1 ANTIBODIES BINDING CANINE PD-L1
    Publication number: 20200109212
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Application
    Filed: December 18, 2019
    Publication date: April 9, 2020
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • PD-L1 antibodies binding canine PD-L1
    Patent number: 10550194
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: February 4, 2020
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Caninized Antibodies
    Publication number: 20190002562
    Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies against canine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: September 13, 2018
    Publication date: January 3, 2019
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • CANINIZED HUMAN ANTIBODIES TO HUMAN IL-4R ALPHA
    Publication number: 20180371097
    Abstract: The present invention provides caninized human anti-human IL-4R? antibodies that have specific sequences and a high binding affinity for canine IL-4R?. The invention also relates to use of these antibodies in the treatment of dogs against atopic dermatitis.
    Type: Application
    Filed: December 15, 2016
    Publication date: December 27, 2018
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang
  • Antibodies to Canine Interleukin-4 Receptor Alpha
    Publication number: 20180346580
    Abstract: The present invention discloses antibodies and blocking antibodies to canine IL-4 receptor alpha that have specific sequences and a high binding affinity for canine IL-4 receptor ?. The present invention also discloses the use of the antibodies of the present invention in the treatment of atopic dermatitis in dogs. The present invention further discloses unique epitopes that bind to the antibodies to canine IL-4 receptor alpha.
    Type: Application
    Filed: April 1, 2016
    Publication date: December 6, 2018
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang
  • CANINIZED MURINE ANTIBODIES TO HUMAN PD-1
    Publication number: 20180346570
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Application
    Filed: June 13, 2018
    Publication date: December 6, 2018
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard Presta
  • Caninized antibodies
    Patent number: 10106607
    Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies againstcanine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 23, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • ANTIBODIES AGAINST CANINE PD-1
    Publication number: 20180251554
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: February 12, 2018
    Publication date: September 6, 2018
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • PD-L1 ANTIBODIES BINDING CANINE PD-L1
    Publication number: 20180237535
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Application
    Filed: September 29, 2015
    Publication date: August 23, 2018
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Caninized murine antibodies to human PD-1
    Patent number: 10023636
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 17, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard G. Presta
  • Antibodies against canine PD-1
    Patent number: 9944704
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: April 17, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • ANTIBODIES AGAINST CANINE PD-1
    Publication number: 20160333096
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 17, 2016
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • CANINIZED MURINE ANTIBODIES TO HUMAN PD-1
    Publication number: 20160319018
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 3, 2016
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard G. Presta